Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 21, 2023

Amivantamab Plus Chemotherapy With or Without Lazertinib for EGFR-Mutant Advanced NSCLC After Disease Progression on Osimertinib

Annals of Oncology


Additional Info

Annals of Oncology
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase 3 MARIPOSA-2 study
Ann. Oncol 2023 Oct 23;[EPub Ahead of Print], A Passaro, J Wang, Y Wang, SH Lee, B Melosky, JY Shih, J Wang, K Azuma, O Juan-Vidal, M Cobo, E Felip, N Girard, AB Cortot, R Califano, F Cappuzzo, S Owen, S Popat, JL Tan, J Salinas, P Tomasini, RD Gentzler, WN William, KL Reckamp, T Takahashi, S Ganguly, DM Kowalski, A Bearz, M MacKean, P Barala, AB Bourla, A Girvin, J Greger, D Millington, M Withelder, J Xie, T Sun, S Shah, B Diorio, RE Knoblauch, JM Bauml, RG Campelo, BC Cho

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading